CD160 Expression in Corneal Vessels

Recruiting

• Conditions: Lymphangiogenesis; Angiogenesis; Corneal Graft Rejection; CD160
• Interventions: Biological: Immunohistochemistry and clinical analyses on patients and corneas

• Registration Number: NCT05009407
• Lead Sponsor: CHU de Reims

Brief Summary

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Detailed Description

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included.

Routine general and eye examination including cornea photographs will be performed.

During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Study Timeline

• Study Start: 2021-04-21
• Study First Submitted: 2021-08-03
• Study First Submitted QC: 2021-08-11
• Study First Posted: 2021-08-17
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-12
• Last Update Posted: 2024-04-15
• Primary Completion: 2024-07-21
• Study Completion: 2024-07-21

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HOSTS	Immunohistochemistry and clinical analyses on patients and corneas	patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
DONORS	Immunohistochemistry and clinical analyses on patients and corneas	grafts from donors that would be analyzed

Primary Outcome Measures

Name	Time	Method
Micro-vascular densities	1 year	neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160

Secondary Outcome Measures

Name	Time	Method
Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA	1 year
Evaluation of clinical blood vascular densities on photographs with help of ImageJ software	1 year

Trial Locations

Locations (1)

Damien JOLLY; 🇫🇷 Reims, France